Thursday, February 22, 2024

 

Amyloidosis is a rare, debilitating and often fatal set of diseases. Early recognition is vital for therapy to have a meaningful effect on survival and patient quality of life. Please join us to hear amyloidosis expert Morie A. Gertz, M.D., discuss the critical need for earlier diagnosis in as well as the merits of conventional and high-dose therapy for disease management.

MORE INFORMATION AND REGISTER >>

Learning Objectives

Upon completion of this conference, participants should be better able to:

• Recognize clinical situations in which AL amyloidosis should be seriously considered in differential.
• Weigh the merits of conventional and high-dose therapy as management for AL amyloidosis.
• Apply evidence-based recommendations that allow for earlier diagnosis of this rare set of diseases and enable accurate staging and counseling about prognosis.